area of tissue is known as percent mammographic density ( PMD ). Breast Density Measurement Recognition of breast density as a breast cancer risk factor and measurement of density have been evolving for more than 30 years. This affects a large number
Search Results
Renee W. Pinsky and Mark A. Helvie
Anne K. Hubben, Nathan Pennell, Marc Shapiro, Craig Savage, and James P. Stevenson
chemotherapy initiated between January 2016 and August 2018. PP pGCSF use was appropriate if prescribed with chemotherapy regimens with a high risk (>20%) for FN, or intermediate risk (10%–20%) if other accepted FN risk factors were present. PP use with FN low
Doralina L. Anghelescu, Jennifer Harman Ehrentraut, and Lane G. Faughnan
Treatment of chronic pain with opioids is associated with the risk of abuse, misuse, diversion, and addiction. 1 Patients receiving chronic opioid therapy (COT) for malignant or nonmalignant pain should be assessed for risk factors of abuse and
Meaghan Tenney and Joan L. Walker
RJ . Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: a Gynecologic Oncology Group study . Gynecol Oncol 1991 ; 40 : 55 – 65 . 5 FIGO . Corpus cancer staging
Douglas E. Wood, Ella A. Kazerooni, Scott L. Baum, George A. Eapen, David S. Ettinger, Lifang Hou, David M. Jackman, Donald Klippenstein, Rohit Kumar, Rudy P. Lackner, Lorriana E. Leard, Inga T. Lennes, Ann N.C. Leung, Samir S. Makani, Pierre P. Massion, Peter Mazzone, Robert E. Merritt, Bryan F. Meyers, David E. Midthun, Sudhakar Pipavath, Christie Pratt, Chakravarthy Reddy, Mary E. Reid, Arnold J. Rotter, Peter B. Sachs, Matthew B. Schabath, Mark L. Schiebler, Betty C. Tong, William D. Travis, Benjamin Wei, Stephen C. Yang, Kristina M. Gregory, and Miranda Hughes
The NCCN Guidelines 1) describe risk factors for lung cancer; 2) recommend criteria for selecting individuals with high-risk factors for screening; 3) provide recommendations for evaluation and follow-up of lung nodules found during screening; 4
Peter L. Greenberg, Richard M. Stone, Rafael Bejar, John M. Bennett, Clara D. Bloomfield, Uma Borate, Carlos M. De Castro, H. Joachim Deeg, Amy E. DeZern, Amir T. Fathi, Olga Frankfurt, Karin Gaensler, Guillermo Garcia-Manero, Elizabeth A. Griffiths, David Head, Virginia Klimek, Rami Komrokji, Lisa A. Kujawski, Lori J. Maness, Margaret R. O’Donnell, Daniel A. Pollyea, Bart Scott, Paul J. Shami, Brady L. Stein, Peter Westervelt, Benton Wheeler, Dorothy A. Shead, and Courtney Smith
DNMT3A, U2AF1, SRSF2, CBL, PRPF8, SETBP1 , and KRAS . 23 , 26 , 29 – 32 Mutations of SF3B1 have been associated with a more favorable prognosis, but this may not be an independent risk factor. 26 , 33 Mutations of TP53 are strongly associated
Swaminathan Murugappan, William P. Harris, Christopher G. Willett, and Edward Lin
cancer, requiring specific multimodality approaches. This article reviews the biology, risk factors, and evolving treatment of LARC. Important advances have been made in the past 3 decades in the multimodality treatment of patients with LARC. In the
Shaneli A. Fernando and Stephen B. Edge
with or without tamoxifen and without radiotherapy: results from five National Surgical Adjuvant Breast and Bowel Project randomized clinical trials . J Clin Oncol 2004 ; 22 : 4247 – 4254 . 7. Wallgren A Bonetti M Gelber RD . Risk factors
Breast cancer risk factor analysis allows the identification of women at very high risk for the future development of breast cancer. However, estimating risk for the individual woman is difficult, and most breast cancers are not attributable to risk factors other than female gender and increased age. These practice guidelines discuss known risk factors, strategies for reducing risk, and possible future developments.
For the most recent version of the guidelines, please visit NCCN.org
Myron Goldsmith, George Whitelaw, and Denise A. Cannaday
. Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients . Cancer 2007 ; 110 : 2339 – 2346 . 11. Wagman LD Baird MF Bennett CL . NCCN Clinical Practice Guidelines in Oncology: Venous Thromboembolic
